Rifat Pamukcu, MD

Dr. Pamukcu is Director, President, and Chief Executive Officer of RxMP Therapeutics, Inc., an emerging specialty therapeutics company focused on developing proprietary drugs for the management of excessive bleeding. Previously, Dr. Pamukcu was a Founder and Director of Cell Pathways, Inc. (CPI) whose mission was to develop drugs for the prevention and treatment of cancer with a focus on Orphan diseases. As Chief Scientific Officer and Executive VP of R&D at CPI, Dr. Pamukcu directed the basic science, preclinical drug development, clinical research, regulatory programs and various aspects of chemical scale-up and manufacturing. Since CPI’s founding in 1989, Dr. Pamukcu was instrumental in raising over $140 million of investment capital and participated in the transformation of CPI to a publicly traded company on NASDAQ. OSI Pharmaceuticals acquired CPI in June 2003. Dr. Pamukcu is currently a Director of Aprea Therapeutics (NASDAQ: APRE), Virion Therapeutics, Syantra, Inc. and SIRPant Immunotherapeutics. He has been an advisor to the Wallace H. Coulter Foundation, and BioComX C3i programs at the NIH and the U.S. Dept. of Veterans Affairs. Dr. Pamukcu has authored over 110 journal articles, book chapters and abstracts. He is an inventor on over 150 issued and pending patents.